JNJ-61186372 is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. JNJ-61186372 was created under a collaboration between Genmab and Janssen using Genmab’s DuoBody technology. The two antibodies used to create JNJ-61186372 were both created by Genmab. JNJ-61186372 is being investigated in a Phase I clinical study to treat NSCLC.

Back to top

Non-small cell lung cancer (NSCLC) accounts for approximately 85% - 90% of all lung cancers. There are three main subgroups of NSCLC, squamous cell carcinoma, adenocarcinoma and large cell carcinoma, which are named after the specific look and chemical makeup of the cancerous cells and how they appear when viewed under a microscope. The program of treatment and outlook for all three subgroups is usually the same1. Most patients with NSCLC are not cured with current treatments2.

1 American Cancer Society, What is non-small cell lung cancer;

2 National Cancer Institute, Non-Small Cell Lung Cancer Treatment;

Back to top